Chemotherapy With or Without Immune Checkpoint Inhibitors for Lung Cancer
NCT ID: NCT05059951
Last Updated: 2024-06-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
15000 participants
OBSERVATIONAL
2021-10-03
2028-03-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Biomarker Development for Lung Cancer Treated With Immune Checkpoint Inhibitors
NCT05055908
Efficacy and Safety of Immunotherapy in Non-small Cell Lung Cancer With Uncommon Histological Type
NCT05023837
Outcomes With Immune Checkpoint Inhibitor for Patients With Non-Small-Cell Lung Cancer and Stable Brain Metastases
NCT05129202
Neoadjuvant Immune Checkpoint Inhibitor Combined With Chemotherapy in Non-small Cell Lung Cancer
NCT04945200
Checkpoint Inhibitors in Patients With Solid Tumors: a Retrospective Real-world Study
NCT05719324
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohort A
Extansive Stage Small Cell Lung Cancer treated with first line Chemotherapy with or without Checkpoint Inhibitors .
Immune checkpoint inhibitor
Chemotherapy follow the guild line.
Cohort B
Limit Stage Small Celll Lung Cancer treated with first line Chemotherapy with or without Checkpoint Inhibitors .
Immune checkpoint inhibitor
Chemotherapy follow the guild line.
Cohort C
Small Celll Lung Cancer who progressed from first line treatment and received subsequential Chemotherapy with or without Checkpoint Inhibitors.
Immune checkpoint inhibitor
Chemotherapy follow the guild line.
Cohort D
Metastastic Non-small cell Lung Cancer treated with first line Chemotherapy with or without Checkpoint Inhibitors.
Immune checkpoint inhibitor
Chemotherapy follow the guild line.
Cohort E
Metastastic Non-small cell Lung Cancer who progressed from first line treatment and received subsequential Chemotherapy with or without Checkpoint Inhibitors.
Immune checkpoint inhibitor
Chemotherapy follow the guild line.
Cohort F
Resectable Non-small cell Lung Cancer treated with first line Chemotherapy with or without Checkpoint Inhibitors.
Immune checkpoint inhibitor
Chemotherapy follow the guild line.
Cohort G
Unresectable Non-small cell Lung Cancer treated with first line Chemotherapy with or without Checkpoint Inhibitors.
Immune checkpoint inhibitor
Chemotherapy follow the guild line.
Cohort H
Non-small cell Lung Cancer received neoadjuvent or adjuvent Chemotherapy with or without Checkpoint Inhibitors.
Immune checkpoint inhibitor
Chemotherapy follow the guild line.
Cohort I
Cohort I, Non-small cell Lung Cancer with EGFR, ALK and ROS1 sensitive mutation who received Chemotherapy with or without Checkpoint Inhibitors.
Immune checkpoint inhibitor
Chemotherapy follow the guild line.
Cohort J
Non-small cell Lung Cancer with other oncogenic mutation including RET, BRAF etc who received Chemotherapy with or without Checkpoint Inhibitors.
Immune checkpoint inhibitor
Chemotherapy follow the guild line.
Cohort K
Non-small cell Lung Cancer received Chemotherapy plus bevacizumab with or without Checkpoint Inhibitors.
Immune checkpoint inhibitor
Chemotherapy follow the guild line.
Cohort L
Non-small cell Lung Cancer who enrolled in clinical trials.
Immune checkpoint inhibitor
Chemotherapy follow the guild line.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Immune checkpoint inhibitor
Chemotherapy follow the guild line.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Treated with Chemotherapy with or Without Checkpoint Inhibitors.
3. ECOG 0 - 1.
4. Predicted survival ≥ 12 weeks.
5. Adequate bone marrow hematopoiesis and organ function
6. Presence of measurable lesions according to RECIST 1.1.
7. Subjects with stable brain metastases may be included in the study.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hunan Province Tumor Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Yongchang Zhang
Professor, Director of Clinical Trial Center
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Yongchang Zhang, MD
Role: PRINCIPAL_INVESTIGATOR
Hunan Cancer Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hunan Cancer Hospital
Changsha, Hunan, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
20210113
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.